Altimmune's 2024 Executive Compensation & Equity Awards Detailed
Ticker: ALT · Form: DEF 14A · Filed: Aug 15, 2025 · CIK: 1326190
| Field | Detail |
|---|---|
| Company | Altimmune, Inc. (ALT) |
| Form Type | DEF 14A |
| Filed Date | Aug 15, 2025 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, equity-awards, corporate-governance
TL;DR
Altimmune dropped its 2024 proxy statement detailing exec pay & stock awards. Check it out.
AI Summary
Altimmune, Inc. filed its DEF 14A on August 15, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including equity awards granted to its Principal Executive Officer (PEO) and Non-PEO/NEO members. It also reports changes in the fair value of outstanding equity awards for the fiscal year 2024.
Why It Matters
This filing provides transparency into how Altimmune compensates its top executives, which can influence investor perception and the company's ability to attract and retain talent.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures about executive compensation and corporate governance, but can sometimes reveal information about potential shareholder concerns or changes in company strategy.
Key Numbers
- 2024 — Fiscal Year (The period covered by the executive compensation and equity award disclosures.)
- 20250925 — Report Date (The period for which the DEF 14A filing is made.)
Key Players & Entities
- Altimmune, Inc. (company) — Filer of the DEF 14A
- 2024-12-31 (date) — Fiscal year end for compensation details
- 20250815 (date) — Filing date of the DEF 14A
FAQ
What is the primary purpose of this DEF 14A filing for Altimmune, Inc.?
The primary purpose is to provide information regarding the company's annual meeting of stockholders, including details on executive compensation, director nominations, and other corporate governance matters for the fiscal year ending December 31, 2024.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on August 15, 2025.
What specific compensation-related data is highlighted in the filing for the fiscal year 2024?
The filing highlights data related to the year-end fair value of equity awards granted in covered years, outstanding and unvested equity awards, and changes in the fair value of outstanding equity awards for both PEO and Non-PEO/NEO members.
Does the filing mention any previous company names for Altimmune, Inc.?
Yes, the filing indicates that Altimmune, Inc. was formerly known as Pharmathene, Inc. (name change on 20071016) and Healthcare Acquisition Corp (name change on 20050505).
What is the business address and phone number provided for Altimmune, Inc.?
The business address is 910 Clopper Road, Suite 201S, Gaithersburg, MD 20878, and the business phone number is 2406541450.
Filing Stats: 4,855 words · 19 min read · ~16 pages · Grade level 11.6 · Accepted 2025-08-15 16:11:17
Key Financial Figures
- $0.0001 — f record of our Common Stock, par value $0.0001 per share (" Common Stock "), at the cl
Filing Documents
- alt-20250925xdef14a.htm (DEF 14A) — 861KB
- alt-20250925xdef14a_a001.jpg (GRAPHIC) — 5KB
- alt-20250925xdef14a_a002.jpg (GRAPHIC) — 5KB
- alt-20250925xdef14a_a003.jpg (GRAPHIC) — 7KB
- alt-20250925xdef14a_a009.jpg (GRAPHIC) — 28KB
- alt-20250925xdef14a_a010.jpg (GRAPHIC) — 28KB
- alt-20250925xdef14a_bg001.jpg (GRAPHIC) — 177KB
- alt-20250925xdef14a_bg002.jpg (GRAPHIC) — 149KB
- 0001326190-25-000046.txt ( ) — 2582KB
- alt-20250925.xsd (EX-101.SCH) — 4KB
- alt-20250925_def.xml (EX-101.DEF) — 3KB
- alt-20250925_lab.xml (EX-101.LAB) — 6KB
- alt-20250925_pre.xml (EX-101.PRE) — 5KB
- alt-20250925xdef14a_htm.xml (XML) — 190KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 25 EXECUTIVE OFFICERS 27
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 28 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 39 OTHER MATTERS 40 i Table of Contents Altimmune, Inc. 910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878 PROXY STATEMENT FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON THURSDAY, SEPTEMBER 25, 2025 GENERAL INFORMATION This Proxy Statement is furnished in connection with a solicitation of proxies by the Board of Directors (the " Board " or " Board of Directors ") of Altimmune, Inc., a Delaware corporation (" Altimmune ," the " Company ," " we " or " our "), to be used at our 2025 Annual Meeting of Stockholders (the " Annual Meeting ") scheduled for Thursday, September 25, 2025, at 8:30 a.m., Eastern Daylight Time. The Annual Meeting will be held virtually at https://www.cstproxy.com/altimmune/2025, where you will be able to vote electronically and submit questions. We invite you to attend the Annual Meeting virtually to vote on the proposals described in this proxy statement. You will need the 12-digit control number included with these proxy materials to attend the annual meeting. This Proxy Statement, the accompanying Notice of Annual Meeting of Stockholders and proxy card are first being mailed to stockholders on or about August 18, 2025. Whenever we refer in this Proxy Statement to the "Annual Meeting," we are also referring to any meeting that results from any postponement or adjournment of the September 25, 2025 meeting. Holders of record of our Common Stock, par value $0.0001 per share (" Common Stock "), at the close of business on August 12, 2025 (the " Record Date ") are entitled to notice of, and to vote at, the Annual Meeting. On that date, there were 88,257,253 shares entitled to be voted. We encourage you to vote your shares, either by voting at the Annual Meeting or by granting a proxy (i.e., authorizing someone to vote your shares). If you vote via the Internet or telephone or execute the attached paper proxy card, the individ